Deranged neuronal calcium signaling and Huntington disease

被引:202
作者
Bezprozvanny, I
Hayden, MR
机构
[1] Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA
[2] Univ British Columbia, Womens & Childrens Hosp, Ctr Mol Med & Therapeut, Dept Med Genet, Vancouver, BC V5Z 1M9, Canada
基金
美国国家卫生研究院; 加拿大健康研究院;
关键词
calcium signaling; huntingtin; neurodegeneration; polyglutamine expansion; inositol 1,4,5-trisphosphate; NMDA; apoptosis; mitochondria;
D O I
10.1016/j.bbrc.2004.08.035
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Huntington disease (HD) is an autosomal-dominant neurodegenerative disorder that primarily affects medium spiny striatal neurons (MSN). HD is caused by polyglutamine (polyQ) expansion (exp) in the amino-terminal region of a protein huntingtin (Htt). The connection between polyQ expansion in Htt(exp) and MSN neurodegeneration remains elusive. Here we discuss recent data that link polyQ expansion in Htt(exp) and deranged Ca2+ signaling in MSN neurons. Experimental evidence indicates that (1) Ca2+ homeostasis is abnormal in mitochondria isolated from lymphoblasts of HD patients and from brains of the YAC72 HD mouse model; (2) Htt(exp) leads to potentiation of NR1/NR2B NMDA receptor activity in heterologous expression systems and in NISN from YAC72 HD mouse model; and (3) Htt(exp) binds to the type 1 inositol 1,4,5-trisphosphate receptor (InsP(3)R1) carboxy-terminus and causes sensitization of InsP(3)R1 to activation by InsP(3) in planar lipid bilayers and in MSN. Based on these results we propose that Htt(exp)- induced cytosolic and mitochondrial Ca2+ overload of MSN plays an important role in the pathogenesis of HD and that Ca2+ signaling blockers may play a beneficial role in treatment of HD. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:1310 / 1317
页数:8
相关论文
共 62 条
[1]   NMDA receptor regulation by Src kinase signalling in excitatory synaptic transmission and plasticity [J].
Ali, DW ;
Salter, MW .
CURRENT OPINION IN NEUROBIOLOGY, 2001, 11 (03) :336-342
[2]  
BEAL MF, 1991, J NEUROSCI, V11, P1649
[3]   REPLICATION OF THE NEUROCHEMICAL CHARACTERISTICS OF HUNTINGTONS-DISEASE BY QUINOLINIC ACID [J].
BEAL, MF ;
KOWALL, NW ;
ELLISON, DW ;
MAZUREK, MF ;
SWARTZ, KJ ;
MARTIN, JB .
NATURE, 1986, 321 (6066) :168-171
[4]   Neuronal calcium signaling [J].
Berridge, MJ .
NEURON, 1998, 21 (01) :13-26
[5]   Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia [J].
Browne, SE ;
Bowling, AC ;
MacGarvey, U ;
Baik, MJ ;
Berger, SC ;
Muqit, MMK ;
Bird, ED ;
Beal, MF .
ANNALS OF NEUROLOGY, 1997, 41 (05) :646-653
[7]   Subtype-specific enhancement of NMDA receptor currents by mutant Huntingtin [J].
Chen, NS ;
Luo, T ;
Wellington, C ;
Metzler, M ;
McCutcheon, K ;
Hayden, MR ;
Raymond, LA .
JOURNAL OF NEUROCHEMISTRY, 1999, 72 (05) :1890-1898
[8]  
CHOI DW, 1995, TRENDS NEUROSCI, V18, P58
[9]   LESION OF STRIATAL NEURONS WITH KAINIC ACID PROVIDES A MODEL FOR HUNTINGTONS-CHOREA [J].
COYLE, JT ;
SCHWARCZ, R .
NATURE, 1976, 263 (5574) :244-246
[10]   LOSS OF ENDOPLASMIC RETICULUM-ASSOCIATED ENZYMES IN AFFECTED BRAIN-REGIONS IN HUNTINGTONS-DISEASE AND ALZHEIMER-TYPE DEMENTIA [J].
CROSS, AJ ;
CROW, TJ ;
JOHNSON, JA ;
DAWSON, JM ;
PETERS, TJ .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1985, 71 (2-3) :137-143